|
|
| Gene | [FZD9](/genes/fzd9) |
| UniProt ID | O00187 |
| PDB ID | 7D8K |
| Molecular Weight | 63,500 Da |
| Subcellular Localization | Plasma membrane |
| Protein Family | Frizzled receptor family (Class F) |
| Brain Expression | Hippocampus, cortex, cerebellum, olfactory bulb |
| Chromosome | 7q11.23 (Williams syndrome region) |
| Amino Acids | 647 |
FZD9 (Frizzled-9) is a member of the Frizzled family of seven-transmembrane receptors that mediate Wnt signaling. Notably, the FZD9 gene is located within the Williams syndrome deletion region on chromosome 7q11.23, making it haploinsufficient in individuals with this neurodevelopmental disorder. FZD9 plays critical roles in brain development, synaptic plasticity, and cognitive function 1.
FZD9 is unique among Frizzled receptors due to its highly restricted expression pattern in the brain and its clear association with a human genetic syndrome. The receptor is essential for proper hippocampal development, cerebellar function, and social behavior, making it a key molecule in understanding both neurodevelopment and neurodegeneration.
FZD9 possesses the characteristic architecture of Frizzled receptors:
¶ Extracellular Domain
¶ Cysteine-Rich Domain (CRD)
The N-terminal CRD contains 10 conserved cysteine residues forming five disulfide bonds, creating a compact protein interaction module. This domain serves as the primary Wnt ligand-binding interface with distinct binding properties compared to other Frizzled receptors 2.
Key structural features:
- Wnt-binding pocket: Hydrophobic groove accommodating Wnt lipid modification
- Dimerization interface: Enables receptor dimerization for signal modulation
- Glycosylation sites: N-linked glycans affect ligand binding kinetics
The extracellular linker between CRD and the first transmembrane helix is relatively short, facilitating rapid ligand-induced conformational changes.
¶ Transmembrane Domain
Seven transmembrane helices in the typical Frizzled configuration:
- TM1-TM7: Seven-pass transmembrane architecture
- Conserved motifs: "CW" sequence in TM6, proline-induced kinks
- GPCR-like fold: Structural similarity to G-protein-coupled receptors
¶ Intracellular Domain
The C-terminal tail contains:
- Multiple Ser/Thr residues: Phosphorylation sites for signal modulation
- PDZ-binding motif: -(S/T)-X-Φ at the C-terminus for scaffold protein interactions
- DVL binding sites: Interface for downstream signaling effectors
FZD9 functions as a receptor for multiple Wnt ligands including WNT1, WNT2, WNT3, WNT3A, and WNT5A. Upon ligand binding, FZD9 recruits Dishevelled (DVL) proteins to initiate downstream signaling that stabilizes β-catenin and drives target gene expression 3.
Wnt ligand → FZD9 → DVL → β-catenin stabilization → TCF/LEF → Gene expression
- Transcription factors: MYC, CCND1, AXIN2
- Synaptic proteins: SYNAPSIN, PSD-95
- Cell survival factors: BCL-2, Survivin
FZD9 is essential for multiple aspects of neural development:
- Regulates neural progenitor proliferation in the ventricular zone
- Controls cortical layering through neuronal migration
- Influences dendrite formation and arborization
- Essential for CA1/CA3 pyramidal neuron development
- Regulates dentate gyrus granule cell maturation
- Critical for mossy fiber tract formation
- Controls inhibitory interneuron development
- Regulates Purkinje cell dendritic development
- Controls granule cell migration
- Essential for motor learning circuitry
- Promotes both excitatory and inhibitory synapse formation
- Regulates synaptic vesicle protein expression
- Controls postsynaptic density organization
In mature neurons, FZD9 continues to play important roles:
- Required for hippocampal LTP induction
- Couples to NMDA receptor function
- Regulates AMPA receptor trafficking
- Mediates Wnt-dependent LTD
- Controls mGluR-dependent plasticity
¶ Learning and Memory
- FZD9 knockout mice show spatial memory deficits
- Impaired contextual fear conditioning
- Reduced hippocampal LTP
FZD9 haploinsufficiency due to the 7q11.23 microdeletion contributes significantly to the Williams syndrome phenotype:
- Intellectual disability: IQ typically 55-70
- Hyperacusis: Heightened auditory sensitivity
- Social disinhibition: Excessive friendliness
- Language delay: Particularly expressive language
- Altered brain development, particularly hippocampus
- Impaired spatial cognition
- Social behavior abnormalities
- Cerebellar dysfunction
| Williams Syndrome Feature |
FZD9 Contribution |
| Spatial deficits |
Hippocampal maldevelopment |
| Social behavior |
Amygdala/cortex effects |
| Language delay |
Cerebellar involvement |
| Motor coordination |
Purkinje cell dysfunction |
- Wnt agonist therapy may partially compensate
- Early intervention to support development
- Gene therapy approaches under investigation
FZD9 dysregulation contributes to AD pathogenesis:
- FZD9 mRNA reduced in AD hippocampus
- Protein levels decrease with disease progression
- Correlates with cognitive decline
- Impaired Wnt signaling: Reduces neuroprotective signaling
- Synaptic dysfunction: Contributes to synapse loss
- Neurogenesis impairment: Reduces hippocampal neurogenesis
- Aβ interaction: Aβ interferes with FZD9 signaling
- FZD9 agonists may restore Wnt signaling
- Protective against Aβ toxicity
- May enhance hippocampal neurogenesis
FZD9 has emerging roles in PD:
- Expressed in substantia nigra pars compacta
- Provides neuroprotection for dopaminergic neurons
- Regulates mitochondrial function
- Reduced FZD9 in PD substantia nigra
- Correlates with disease severity
- Wnt/FZD9 signaling protects against MPTP toxicity
- May support dopaminergic neuron survival
FZD9 has context-dependent roles in cancer:
- Often downregulated in cancers
- Functions as tumor suppressor in certain contexts
- Loss promotes tumorigenesis
- Reduced: Colorectal, gastric cancers
- Maintained: Some brain tumors
- Altered: Context-specific
graph TD
A["WNT1/2/3/3A/5A"] --> B["FZD9"]
B --> C["DVL1/2/3"]
C -->|"Canonical"| D["β-catenin"]
C -->|"PCP"| E["PCP Effectors"]
C -->|"Ca²⁺"| F["Ca²⁺ Signaling"]
D --> G["TCF/LEF"]
G --> H["Gene Transcription"]
D --> I["Cell Survival"]
E --> J["Cytoskeleton"]
F --> K["CaMKII"]
| Interaction Partner |
Interaction Type |
Functional Consequence |
| WNT1, WNT2, WNT3, WNT3A |
Ligand binding |
Activates canonical signaling |
| WNT5A |
Ligand binding |
Activates non-canonical signaling |
| DVL1, DVL2, DVL3 |
Direct binding |
Signal transduction |
| LRP5, LRP6 |
Co-receptor |
Enhances canonical pathway |
| β-catenin |
Downstream effector |
Gene transcription |
| DAB2 |
Scaffold protein |
Modulates signaling |
FZD9 expression is regulated by:
- Developmental factors: Pax6, Otx2 in CNS
- Epigenetic mechanisms: DNA methylation
- Cellular context: Activity-dependent regulation
| Modification |
Effect |
| Palmitoylation |
Required for receptor function |
| Phosphorylation |
Modulates signal output |
| Ubiquitination |
Receptor turnover |
| Glycosylation |
Stability and trafficking |
- Wnt agonist therapy to compensate for haploinsufficiency
- Early developmental intervention
- Gene therapy to restore FZD9 expression
- FZD9-specific agonists
- Wnt pathway activators
- Combined approaches with other Wnt receptors
- FZD9 neuroprotection for dopaminergic neurons
- Mitochondrial function enhancement
- Combined with other neurotrophic approaches
- Knockout mice: FZD9-deficient mice recapitulate WS features
- iPSC models: Patient-derived neurons for drug testing
- Organoids: Brain organoids for developmental studies